Ehrlich Christopher B
SEC-identified person · CIK 1293973 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Phoenix Biotech Acquisition Corp. PBAX | Director · Interim Chairman and CEO | filed 2021–2026 |
| Launch One Acquisition Corp. LPAAU | Director · Chief Executive Officer | filed 2024–2024 |
| Effector Therapeutics, Inc. LWAC | Director · See Remarks | filed 2021–2024 |
| Transcept Pharmaceuticals Inc TSPT | Director | filed 2009–2013 |
| Biomimetic Therapeutics, INC. bmti | Director | filed 2006–2013 |
| Tesaro, Inc. TSRO | Officer | filed 2012–2012 |
| Trius Therapeutics Inc TSRX | Officer | filed 2010–2010 |
| Corgentech INC CGTK | Officer | filed 2006–2007 |
| Reshape Weightloss Inc. etrm | Officer | filed 2007–2007 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.